Azenta, Inc.AZTAEarnings & Financial Report
Azenta, was founded in 1978, and is based in Chelmsford, Massachusetts, United States. The company is a provider of life sciences services including genomics, cryogenic storage, automation, and informatics.
AZTA Q1 2026 Key Financial Metrics
Revenue
$148.6M
Gross Profit
$63.7M
Operating Profit
$-7.2M
Net Profit
$-15.4M
Gross Margin
42.9%
Operating Margin
-4.9%
Net Margin
-10.4%
YoY Growth
0.8%
EPS
$-0.34
Financial Flow
Azenta, Inc. Q1 2026 Financial Summary
Azenta, Inc. reported revenue of $148.6M for Q1 2026, with a net profit of $-15.4M (-10.4% margin). Cost of goods sold was $84.9M, operating expenses totaled $70.9M.
Key Financial Metrics
| Total Revenue | $148.6M |
|---|---|
| Net Profit | $-15.4M |
| Gross Margin | 42.9% |
| Operating Margin | -4.9% |
| Report Period | Q1 2026 |
Azenta, Inc. Annual Revenue by Year
Azenta, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $593.8M).
| Year | Annual Revenue |
|---|---|
| 2025 | $593.8M |
| 2024 | $656.3M |
| 2023 | $665.1M |
| 2022 | $555.5M |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $159.1M | $172.8M | $170.1M | $147.5M | $143.4M | $143.9M | $159.0M | $148.6M |
| YoY Growth | 7.2% | 4.1% | -1.3% | -4.4% | -9.9% | -16.7% | -6.5% | 0.8% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.56B | $2.32B | $2.10B | $2.04B | $2.04B | $2.02B | $2.06B | $2.07B |
| Liabilities | $340.6M | $332.9M | $331.1M | $322.2M | $340.4M | $345.5M | $332.6M | $359.6M |
| Equity | $2.22B | $1.99B | $1.77B | $1.72B | $1.70B | $1.67B | $1.73B | $1.71B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $8.4M | $1.8M | $13.7M | $30.6M | $13.6M | $25.8M | $2.2M | $20.8M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M